Peter Max
- CEO Partner
Transaction Description
Stenocare had prepared to add a further financial instrument at the General Meeting on Friday November 18, 2022. The new instrument was a convertible loan facility of up to 11 mDKK, that enabled the company to issue loans (convertible bonds) where the lenders had the opportunity to convert to shares at a price that is fixed to 25% above market-price on issue.
Contact Person
Company Description
Stenocare is a Danish pharmaceutical company founded in 2017. Already the following year, Stenocare became the first Danish company to obtain permits to cultivate, import, and handle medical cannabis oils in the Danish pilot Programme. Simoultaneously, Stenocare is the first Danish company to have obtained approval for medical oil-based cannabis products for the Danish pilot Programme. Today, Stenocare operates in Denmark, Sweden, Norway, Germany, the UK, and Australia.